News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
Alleviating staff shortages by empowering surgeons with greater personalization and control
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
The generous donation includes multiple medical equipments
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Subscribe To Our Newsletter & Stay Updated
